SCHEDULE: Takeda Boosts Ovid Therapeutics Stake to 12.3%

Takeda Pharmaceutical Company Limited and its subsidiary Takeda Pharmaceuticals U.S.A., Inc. reported an aggregate beneficial ownership of 12.3% in Ovid Therapeutics Inc. common stock.

Summary

• Takeda Pharmaceutical Company Limited and its subsidiary Takeda Pharmaceuticals U.S.A., Inc. collectively hold 8,781,996 shares of Ovid Therapeutics Inc. common stock.
• This represents 12.3% of Ovid Therapeutics Inc.'s outstanding common stock.
• Takeda Pharmaceutical Company Limited directly holds 1,781,996 shares.
• Takeda Pharmaceuticals U.S.A., Inc. holds 7,000,000 shares, which Takeda Pharmaceutical Company Limited indirectly beneficially owns through its wholly-owned subsidiary structure.
• The percentage is based on 71,212,353 shares of common stock issued and outstanding as of November 7, 2025, as reported in Ovid Therapeutics Inc.'s Quarterly Report on Form 10-Q.

Sentiment

Score: 5

Explanation: The filing is a routine disclosure of beneficial ownership, indicating a neutral sentiment. It provides factual information without expressing positive or negative outlooks or operational changes.

Management Comments

• The securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11.

Industry Context

This filing indicates a significant, passive investment by a major global pharmaceutical company, Takeda, in Ovid Therapeutics, a biotechnology firm. Such strategic investments are common in the pharmaceutical industry, often signaling potential future collaborations or a belief in the target company's pipeline or market position, even if the stated intent is passive.

Related Party Transactions

• Takeda Pharmaceutical Company Limited indirectly beneficially owns 7,000,000 shares held by its wholly-owned subsidiary, Takeda Pharmaceuticals U.S.A., Inc.

Stakeholder Impact

• Shareholders of Ovid Therapeutics Inc. now have clarity on the significant ownership stake held by Takeda, a major pharmaceutical entity, which could be perceived as a vote of confidence in the company's long-term prospects.
• The substantial ownership by Takeda could influence Ovid Therapeutics Inc.'s strategic decisions or future partnerships, although Takeda has certified its intent as a passive investor.

Key Dates

Keywords

Ovid Therapeutics, Takeda Pharmaceutical, Takeda Pharmaceuticals USA, Schedule 13G, Beneficial Ownership, Common Stock, Biotechnology, Pharmaceuticals, Investment, Stake